TLR4与N-HDL-C在冠心病中的表达及辛伐他汀的干预机制(3)
参考文献
[1] Pedersen，Terje R.The success story of LDL cholesterol lowering[J].Circulation Research，2016，118(4)：721-731.
[2] Ross R.Athemsclerosis-an inflammatory disease[J].The New England Journal of Medicine，1999，340(2)：115-126.
[3] Ridker P M，Everett B M，Thuren T，et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease[J].New England Journal of Medicine，2017，377(12)：1119-1131.
[4]程翔.冠心病的抗炎治療：历经艰辛终见彩虹[J].中华心血管病杂志，2018，46(5)：341-343.
[5] Sigdle M，Yadav B K，Gyawail P，et al.Non-high density lipoprotein cholesterol versues low density lipoprotein cholesterol as a discriminating factor for myocarcial infarction[J].BMC Research Notes，2012(5)：640-645.
[6] Satoh M，Takahashi Y，Tabuchi T，et al.Cellular and molecular mechanisms of statins：an update on pleiotropic effects[J].Clinical Science，2015，129(2)：93-105.
[7] Liu M，Tang R，Jiang Y.Study on the function and mechanism of atorvastion in regulating leukemic cell apoptosis by the P13K/Akt pathway[J].International Journal of Clinical & Experimental Medicine，2015，8(3)：3371-3380.
[8] Baigent C，Keech A，Keamey P M，et al.Efficacy and safety of cholesterol-lowering treatment：prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins[J].Lancet，2005，366(9493)：1267-1278.
[9]赵水平.《中国成人血脂异常防治指南(2016年修订版)》要点与解读[J].中华心血管病杂志，2016，44(10)：827-829.
[10] Methe H，Kim J O，Kofler S，et al.Expansion of circulating TLR4-positive monocytes in patients with ACS[J].Circulation，2005，111(20)：2654-2661.
[11]李玉红，谢萍，李远，等.急性冠脉综合征患者TOLL样受体4的变化及通心络的干预作用[J].临床心血管病杂志，2014，255(9)：776-778.
[12] Fang D，Yang S，Quan W，et al.Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques[J].European Review for Medical and Pharmacological Sciences，2014，18(2)：242-246.
[13] Zeuke S，Ulmer A J，Kusumoto S，et al.TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS[J].Cardiovascular Research，2002，65(3)：126-134.
(收稿日期：2019-11-04) (本文编辑：李盈), http://www.100md.com(李玉红 谢萍 李远 谢辉 洪有勤 陈勇)
[1] Pedersen，Terje R.The success story of LDL cholesterol lowering[J].Circulation Research，2016，118(4)：721-731.
[2] Ross R.Athemsclerosis-an inflammatory disease[J].The New England Journal of Medicine，1999，340(2)：115-126.
[3] Ridker P M，Everett B M，Thuren T，et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease[J].New England Journal of Medicine，2017，377(12)：1119-1131.
[4]程翔.冠心病的抗炎治療：历经艰辛终见彩虹[J].中华心血管病杂志，2018，46(5)：341-343.
[5] Sigdle M，Yadav B K，Gyawail P，et al.Non-high density lipoprotein cholesterol versues low density lipoprotein cholesterol as a discriminating factor for myocarcial infarction[J].BMC Research Notes，2012(5)：640-645.
[6] Satoh M，Takahashi Y，Tabuchi T，et al.Cellular and molecular mechanisms of statins：an update on pleiotropic effects[J].Clinical Science，2015，129(2)：93-105.
[7] Liu M，Tang R，Jiang Y.Study on the function and mechanism of atorvastion in regulating leukemic cell apoptosis by the P13K/Akt pathway[J].International Journal of Clinical & Experimental Medicine，2015，8(3)：3371-3380.
[8] Baigent C，Keech A，Keamey P M，et al.Efficacy and safety of cholesterol-lowering treatment：prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins[J].Lancet，2005，366(9493)：1267-1278.
[9]赵水平.《中国成人血脂异常防治指南(2016年修订版)》要点与解读[J].中华心血管病杂志，2016，44(10)：827-829.
[10] Methe H，Kim J O，Kofler S，et al.Expansion of circulating TLR4-positive monocytes in patients with ACS[J].Circulation，2005，111(20)：2654-2661.
[11]李玉红，谢萍，李远，等.急性冠脉综合征患者TOLL样受体4的变化及通心络的干预作用[J].临床心血管病杂志，2014，255(9)：776-778.
[12] Fang D，Yang S，Quan W，et al.Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques[J].European Review for Medical and Pharmacological Sciences，2014，18(2)：242-246.
[13] Zeuke S，Ulmer A J，Kusumoto S，et al.TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS[J].Cardiovascular Research，2002，65(3)：126-134.
(收稿日期：2019-11-04) (本文编辑：李盈), http://www.100md.com(李玉红 谢萍 李远 谢辉 洪有勤 陈勇)